Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis
Abstract Rituximab combined with chemotherapy is the first-line induction therapy of CD20 positive B-cell non-Hodgkin lymphomas (CD20+ B-NHL). Recently new anti-CD20 monoclonal antibodies (mAbs) have been developed, but their efficacy and safety compared with rituximab are still controversial. We se...
Guardado en:
Autores principales: | Chengxin Luo, Guixian Wu, Xiangtao Huang, Yanni Ma, Yali Zhang, Qiuyue Song, Mingling Xie, Yanni Sun, Yarui Huang, Zhen Huang, Yu Hou, Shuangnian Xu, Jieping Chen, Xi Li |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/09e7bf5118624eba86020226d2018c5e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression
por: Song L, et al.
Publicado: (2019) -
Uso del rituximab(anticuerpo monoclonal anti-CD20) en lupus eritematoso sistémico refractario a tratamiento: Caso clínico
por: Sabugo S,Francisca, et al.
Publicado: (2005) -
Statins impair antitumor effects of rituximab by inducing conformational changes of CD20.
por: Magdalena Winiarska, et al.
Publicado: (2008) -
Rituximab in the treatment of non-Hodgkin’s lymphoma
por: Beate Hauptrock, et al.
Publicado: (2008) -
Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab
por: Carla Serra-Peinado, et al.
Publicado: (2019)